Unity Biotechnology

Unity Biotechnology is a United States-based company focused on developing new medicines to harness the biology of aging and address retinal diseases. The company's lead senolytic candidate, UBX1325, has shown promising results in a Phase 2 study for diabetic macular edema, demonstrating sustained and clinically meaningful improvements in vision.